US2020009049A1PendingUtilityA1
Generation of therapeutic microfoam
Est. expiryMay 26, 2019(expired)· nominal 20-yr term from priority
Inventors:Tariq OsmanSheila Bronwen Shilton-BrownDavid D. WrightAnthony David HarmanTimothy David Boorman
A61P 9/14A61P 9/00B65D 83/60B05B 7/0037B65D 83/20B65D 83/62A61K 9/0019B65D 83/14B65D 83/48B05B 11/02A61M 5/31A61K 31/08A61K 9/122A61K 9/12B65D 83/16B65D 83/58
70
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Improved therapeutic sclerosing microfoams and methods and devices for making them are provided that have advantage in producing a consistent profile injectable foam with minimal input by the physician yet using high volume percentages of blood dispersible gases, thus avoiding use of potentially hazardous amounts of nitrogen.
Claims
exact text as granted — not AI-modified1 - 67 . (canceled)
68 . A microfoam comprising a gas component and an aqueous sclerosant liquid wherein the microfoam is produced by passing the gas component and the aqueous sclerosant liquid through one or more passages, each passage having a diameter greater than about 5 μm and less than about 25 μm, wherein:
the gas component comprises a physiologically acceptable blood dispersible gas including a mixture of oxygen and carbon dioxide,
the aqueous sclerosant liquid comprises at least one sclerosing agent chosen from polidocanol and sodium tetradecylsulfate (STS), and
the microfoam comprises gas bubbles, at least 95% by number of the gas bubbles having a diameter less than 250 μm.
69 . The microfoam of claim 68 , wherein the physiologically acceptable blood dispersible gas comprises 10 to 99% vol/vol carbon dioxide.
70 . The microfoam of claim 69 , wherein the physiologically acceptable blood dispersible gas comprises a mixture of 10 to 99% vol/vol carbon dioxide with the remainder oxygen.
71 . The microfoam of claim 68 , wherein the physiologically acceptable blood dispersible gas comprises 20 to 99% vol/vol carbon dioxide.
72 . The microfoam of claim 71 , wherein the physiologically acceptable blood dispersible gas comprises a mixture of 20 to 99% vol/vol carbon dioxide with the remainder oxygen.
73 . The microfoam of claim 68 , wherein the physiologically acceptable blood dispersible gas comprises 10 to 40% vol/vol carbon dioxide.
74 . The microfoam of claim 73 , wherein the physiologically acceptable blood dispersible gas comprises a mixture of 10 to 40% carbon dioxide vol/vol with the remainder oxygen.
75 . The microfoam of claim 68 , wherein the physiologically acceptable blood dispersible gas comprises 20 to 30% vol/vol carbon dioxide.
76 . The microfoam of claim 75 , wherein the physiologically acceptable blood dispersible gas comprises a mixture of 20 to 30% carbon dioxide vol/vol with the remainder oxygen.
77 . The microfoam of claim 68 , wherein the density of the microfoam ranges from 0.07 g/ml to 0.19 g/ml.
78 . The microfoam of claim 68 , wherein a ratio of gas to liquid is such that the microfoam that is produced has a half-life of at least two minutes.
79 . The microfoam of claim 68 , wherein the aqueous sclerosant liquid is a solution of polidocanol in an aqueous carrier or sodium tetradecylsulfate (STS) in an aqueous carrier.
80 . The microfoam of claim 68 , wherein the aqueous sclerosant liquid comprises 1% vol/vol polidocanol in an aqueous carrier.
81 . The microfoam of claim 68 , wherein the aqueous sclerosant liquid is a solution of polidocanol in an aqueous carrier having a concentration of polidocanol from 0.5 to 4% vol/vol in the solution.
82 . The microfoam of claim 68 , wherein the aqueous sclerosant liquid further comprises glycerol.
83 . The microfoam of claim 68 , wherein the gas component comprises a physiologically acceptable blood dispersible gas including a mixture of oxygen and carbon dioxide and other physiological gases, the other physiological gases including less than 40% vol/vol nitrogen.
84 . The microfoam of claim 83 , wherein the physiologically acceptable blood dispersible gas comprises 10 to 99% vol/vol carbon dioxide.
85 . The microfoam of claim 83 , wherein the physiologically acceptable blood dispersible gas comprises 10 to 40% vol/vol carbon dioxide.Join the waitlist — get patent alerts
Track US2020009049A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.